Both high and low doses of SGLT-2 inhibitors were associated with a reduced risk of 12 cardiopulmonary diseases (e.g., bradycardia, atrial fibrillation, hypertensive emergencies, asthma, chronic obstructive pulmonary disease, and sleep apnea syndrome) (Zou et al., 2022). The gene discussed is SLC5A2; the disease is asthma.